Aura Biosciences, Inc.: updates and filings

AURANASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$6.87

November 20, 2026Market cap $715M

What Ploutos Investor adds for Aura Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 30, 2026 latest annualNov 9, 2026 latest quarterly
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 9, 2026Results of operations, other material events
    Form8-K
  • Oct 27, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Shares registered for employees
    FormS-8
  • Aug 20, 2026Filing
    FormEFFECT
  • Aug 18, 2026Correspondence with the SEC
    FormCORRESP
  • Aug 17, 2026Letter from the SEC
    FormUPLOAD
  • Aug 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 14, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 11, 2026Shelf registration for future offerings
    FormS-3
  • Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 11, 2026Results of operations, restructuring costs, officer or director change, other material events
    Form8-K
  • Aug 5, 2026Shareholder vote
    Form8-K
  • Jul 27, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jul 8, 2026Officer or director change
    Form8-K
  • Jun 29, 2026Annual meeting proxy statement
    FormDEF 14A
  • Jun 17, 2026Preliminary proxy statement
    FormPRE 14A
  • Jun 11, 2026Shareholder vote
    Form8-K
  • May 19, 2026Shares registered for employees
    FormS-8
  • May 12, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 21, 2010.

The full analysis

What do Aura Biosciences's filings show?

The filings are where every one of Aura Biosciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.